Markets Edge — Capital flows, CMO moves, M&A

ISABELLA'S ISLAY M&A Intelligence Apr 28, 5:01 PM EDT

Apollo Global Management / Nippon Sheet Glass

WSJ ↗

Apollo acquires Nippon Sheet Glass for $3.7B, enters manufacturing

Apollo Global Management agreed to acquire Nippon Sheet Glass in a $3.7 billion deal, marking the firm's expansion into industrial manufacturing and materials.

ReadingManufacturing consolidation is moving upmarket. Operators in materials, glass, and building supplies need to assume they are on someone's acquisition list.

WatchApollo's first earnings report post-close. Management will guide on integration costs and margin accretion timelines. Expect conservative guidance.

Read full analysis → Original ↗

m&aprivate equitymanufacturingglass

HENRI IV M&A Intelligence Apr 28, 5:01 PM EDT

S&P Global / Motive Partners

S&P Global ↗

S&P Global buys Motive's private markets platform for $1.8B

S&P Global agreed to acquire With Intelligence, a private markets data and analytics platform backed by Motive Partners, for $1.8 billion, expanding its leadership in alternative assets.

ReadingInstitutional asset managers are now utilities, not growth stories. The real economics flow to the data layer underneath them. Operators in alternative assets should assume their data is more valuable than their fund performance.

WatchS&P Global's next integration hire. The platform will need a head of product to cannibalize existing S&P offerings and rebuild from the With Intelligence product stack. That hire happens within 45 days.

Read full analysis → Original ↗

m&adata infrastructureprivate marketsfintech

MACALLAN 1926 Healthcare Intelligence Apr 28, 5:01 PM EDT

Arcellx / Gilead Sciences

Stock Titan ↗

Gilead to acquire Arcellx for $115 per share plus contingent payment

Gilead Sciences agreed to acquire Arcellx, a cell therapy company, for $115 per share in cash plus potential contingent value rights, expanding Gilead's position in oncology and immunology.

ReadingSingle-asset biotech companies trading under $2B market cap should assume they are acquisition targets. The probability of independent success at late stage is declining. Gilead's move sets the pricing frame for similar deals.

WatchArcellx's clinical trial results over the next two quarters. If efficacy holds, the CVR trigger becomes material. If efficacy slips, Gilead's integration becomes a problem-solving exercise, not a win.

Read full analysis → Original ↗

m&abiotechcell therapyoncology

LOUIS XIII Venture Intelligence Apr 28, 5:01 PM EDT

HawkEye 360 / IPO Market

Aviation Week ↗

HawkEye 360 sets IPO pricing plan, aims for $200M+ raise

HawkEye 360, a geospatial intelligence company, detailed its initial public offering pricing plan, seeking to raise over $200 million to fund satellite expansion and operations.

ReadingPrivate geospatial and satellite companies should accelerate growth narratives now. Public comparables (Maxar, Planet) trade on revenue multiples, not TAM stories. The IPO arbitrage window is narrowing.

WatchHawkEye 360's IPO lock-up expiration. That's when insiders and early investors test the market. The stock's first real price discovery happens 180 days after IPO.

Read full analysis → Original ↗

ipogeospatialspacetechnology

PAPPY 23 Healthcare Intelligence Apr 28, 5:01 PM EDT

Seaport Therapeutics / Hemab

Fierce Biotech ↗

Two biotech firms chart $180M IPO course for depression, clotting programs

Seaport Therapeutics and Hemab announced plans for parallel $180 million initial public offerings, each targeting late-stage clinical candidates in depression and clotting disorders.

ReadingVenture capital in biotech is repricing around IPO likelihood, not exit optionality. Companies that cannot go public within 36 months should assume traditional exit paths are contracting.

WatchSeaport and Hemab's underwriter syndication. The banks' commitment to these parallel IPOs reveals confidence in market appetite. If both firms are backed by the same underwriters, that's a signal of coordinated pricing power.

Read full analysis → Original ↗

ipobiotechpsychiatryhematology

JOHNNIE BLUE Capital Markets Apr 28, 5:01 PM EDT

IPO Market / Multiple

Axios ↗

IPO market records biggest week in years. Breadth signals structural reopening

The IPO market experienced its largest volume week in years, with multiple companies pricing offerings across biotech, technology, and industrial sectors, signaling renewed institutional appetite.

ReadingCompanies with IPO readiness should move within the next 45 days. After that window closes, the market reprices risk. The smart operators go first.

WatchSecondary market pricing action on the first five IPOs to price. If allocations hold or pop, the second wave accelerates. If first-day pops compress below 15%, market appetite is deteriorating.

Read full analysis → Original ↗

ipomarket structurecapital marketsliquidity

WELL POUR M&A Intelligence Apr 28, 5:01 PM EDT

Denver-based PE Firm / Multi-billion acquisition

The Business Journals ↗

Denver PE firm closes unreported multibillion-dollar deal. Identity still unclear

A Denver-based private equity firm reportedly completed a multibillion-dollar acquisition, though terms and target remain undisclosed pending formal announcement.

ReadingSource-watching territory. When the announcement lands—within 30 days—the deal's framing will reveal whether this was opportunistic or strategic.

WatchSEC filings for the next two weeks. Material acquisition announcements typically require 8-K disclosure within 4 business days of close.

Read full analysis → Original ↗

m&aprivate equityundisclosed